



## Cumulative Index 2003

### Volume 14

January	PITUITARY SURGERY, pages 1–180
April	SURGERY FOR PSYCHIATRIC DISORDERS, pages 181–326
July	NEUROAUGMENTATION FOR CHRONIC PAIN, pages 327–468
October	INTRAVENTRICULAR TUMORS, pages 469–655

*Note:* Page numbers of article titles are in **boldface** type.

### A

- Abdominal muscle strength, evaluation of, for pain management, 342
- Abscess, pituitary, imaging of, 71
- N-Acetyl aspartate, in magnetic resonance spectroscopy, in obsessive-compulsive disorder, 214–215
- Acetylcholine modulators, intrathecal delivery of, 361
- Acidophilic stem cell adenoma, 27
- Acromegaly, in somatotroph adenoma, 43–45  
after pituitary surgery, 134, 139–141  
treatment of, 82–83, 139–141
- Adenoassociated virus, for gene transfer, for pain management, 423–424
- Adenohypophysis  
anatomy of, 55–57  
histogenesis of, 13  
histology of, 25  
hormones of, 17–20  
vascular anatomy of, 14–15
- Adenohypophysitis, lymphocytic, imaging in, 72–73, 75
- Adenoma  
acidophilic stem cell, 27  
corticotropin-secreting. *See* Corticotroph adenoma.  
gonadotropin-secreting. *See* Gonadotroph adenoma.  
growth-hormone secreting. *See* Somatotroph adenoma.  
mammosomatotroph, 27–28  
null cell, 34–35  
plurihormonal, 28–29, 36  
prolactin-secreting. *See* Prolactinoma.  
somatotroph. *See* Somatotroph adenoma.  
somatotroph-lactotroph, 27  
thyrotroph. *See* Thyrotroph adenoma.
- Adenovirus, for gene transfer, for pain management, 422–423, 428, 430
- Adrenalectomy, for Cushing's disease, 84
- Aicardi syndrome, choroid plexus tumors in, 472
- Alpha-fetoprotein, in third ventricular tumors, 528
- $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, in pain transmission, 451–452
- Amygdala, connections to, in depression, 216–218
- Analgesia  
intrathecal delivery of. *See* Intrathecal pain management.  
pre-emptive, 452
- Anaplasia, in ependymoma, 473, 573
- Anderson-Fabry disease, pain in, gene therapy for, 431
- Anesthesia dolorosa, deep brain stimulation for, 333
- Aneurysm, suprasellar, imaging of, 75–76
- Angiography  
in choroid plexus tumors, 626  
in intraventricular meningioma, 561  
in neurocytoma, 484  
in subependymal giant cell astrocytoma, 584  
in subependymoma, 579

Angiostatin gene transfer, for pain management, 430–431

Annas, George, on psychiatric neurosurgery regulations, 314

Anticonvulsant action, of vagus nerve stimulation, 276–277, 279–280

Antidepressants, for depression, 201. *See also* Transcranial magnetic stimulation.

Antidiuretic hormone (vasopressin), 21–22  
 deficiency of, after pituitary surgery, 124–126  
 inappropriate secretion of, after pituitary surgery, 126–129  
 regulation of, 123–124  
 replacement of, for diabetes insipidus, 126

Antinociception, physiology of, 452–454

Anxiety disorders, transcranial magnetic stimulation for, 293–294

Arachnoid cyst  
 intraventricular, 609–611  
 parasellar, 63–64

Arachnoid membrane, variants of, 609

Aspartylacylase deficiency, gene therapy for, 431

Astrocytoma  
 hypothalamic, imaging of, 65–66  
 subependymal giant cell, 470–471, 475–476, 584–585  
 third ventricular. *See* Third ventricular tumors.

Ataxia, in third ventricular tumor surgery, 542

## **B**

---

Baclofen, intrathecal delivery of, 360–361

Ballantine, H. Thomas, Jr., on psychiatric neurosurgery, 308

Barber, Jesse, on psychiatric neurosurgery, 311

Behavioral therapy, for obsessive-compulsive disorder, 200–201

Benabid, Alim, deep brain stimulation studies of, 315

Bifrontal transbasal approach, to parasellar and suprasellar lesions, 114–119

Biopsy  
 in third ventricular tumors, 528  
 stereotactic, in neurocytoma, 494

Bipolar mood disorder, thalamocortical dysrhythmia in. *See* Thalamocortical dysrhythmia.

Bleeding. *See* Hemorrhage.

Body dysmorphic disorder, neuroimaging and neurocircuitry in, 214

Bone disorders, in acromegaly, 43–44

Bone morphogenic protein gene transfer, for pain management, 430

Brain  
 deep stimulation of. *See* Deep brain stimulation.  
 intraventricular tumors of. *See* Intraventricular tumors.  
 precentral stimulation of, 334, **437–443**  
 sensitization in, physiology of, 450–452

Brain-derived neurotrophic factor, in antinociception, 454

Broca, Paul, localization philosophy of, 181

Bromocriptine  
 for acromegaly, 83  
 for hyperprolactinemia, for prolactinoma, 30, 81–82, 89–90, 143

Burckhardt, Gottlieb, frontal lobotomy procedure of, 181–182

## **C**

---

Cabergoline, for hyperprolactinemia, in prolactinoma, 81–82, 90, 143

Calcification  
 in ependymoma, 473, 572  
 in subependymal giant cell astrocytoma, 584  
 in subependymoma, 475

Calcitonin gene-related peptide, in pain transmission, 446, 452

Calcium, in pain transmission, 451–452

Calcium channel blockers, intrathecal delivery of, 361

Califano, Joseph, psychiatric neurosurgery regulations approved by, 314

Callostomy, for colloid cyst, 609

Camera, for endoscopic intraventricular surgery, 549–550

Canavan disease, gene therapy for, 431

Cancer, metastasis from. *See* Metastasis.

- Cancer pain  
 definition of, 330  
 intrathecal management of, 355, 359, 361, 383–385
- Capsule, internal, anterior limbs of, electrical stimulation of, in obsessive-compulsive disorder, **267–274**
- Capsulotomy, for psychiatric disorders  
 depression, 219, 232–233  
 history of, 191–192  
 obsessive-compulsive disorder, 204–208, 219, 232–233
- Carcinoma  
 choroid plexus  
 clinical features of, 623–624  
 epidemiology of, 469, 621  
 imaging of, 624, 626  
 outcome of, 628–629  
 pathology of, 469–472, 622–623  
 treatment of, 627–628  
 pituitary, 36–37
- Cardiovascular disorders, in acromegaly, 44
- Catheters, for intrathecal pain management, 356–358, 382–383
- Cationic polymers, for gene transfer, 421
- Cauda equina syndrome, in intrathecal medication delivery, 358
- Caudate nucleus  
 anatomy of, 511  
 connections to  
 in depression, 216–219  
 in obsessive-compulsive disorder, 214, 218–219
- Cavernous sinuses  
 anatomy of, for pituitary surgery, 16–17  
 exposure of, in pituitary surgery, 102
- Cavum septum pellucidum, 608
- Cavum veli interpositi, 609
- Cavum vergae, 608–609
- Central neurocytoma. *See* Neurocytoma, intraventricular.
- Central sensitization, physiology of, 450–452
- Cerebellum, hypoplasia of, in Dandy Walker malformation, 613–615
- Cerebral salt wasting, after pituitary surgery, 128
- Cerebrospinal fluid  
 analysis of, in depression, in vagus nerve stimulation, 280  
 leakage of in intrathecal medication delivery, 358
- Chemotherapy  
 for choroid plexus carcinoma, 627–628  
 for ependymoma, 576–577  
 for neurocytoma, 487, 501–503  
 for subependymoma, 583–584
- Chlorpromazine, for psychiatric disorders, history of, 190
- Chlorpropamide, for diabetes insipidus, 132
- Chondrosarcoma, clival, imaging of, 77
- Chordoma, clival, imaging of, 76–77
- Choroid plexus  
 anatomy of, 512–513  
 cysts of, 611–612  
 tumors of  
 clinical features of, 623–624  
 differential diagnosis of, 472  
 epidemiology of, 469, 621  
 genetic features of, 472, 623  
 imaging in, 624, 626  
 in children. *See* Pediatric patients, choroid plexus tumors in.  
 in third ventricle. *See* Third ventricular tumors.  
 metastatic, 598  
 outcome of, 628–629  
 pathology of, 469–472, 621–623  
 subependymal giant cell astrocytoma, 585–586  
 treatment of, 624–628
- Chromaffin cells, intrathecal delivery of, 361
- Cilia, in choroid plexus tumors, 470–471
- Cingulate cortex  
 anterior, connections to  
 in depression, 216–219  
 in obsessive-compulsive disorder, 214, 218–219  
 in nociception, 448
- Cingulotomy, for psychiatric disorders, 191–192, **225–235**  
 anatomic considerations in, 225–227  
 complications of, 230  
 depression, 204–206, 208–209, 218, 225–228  
 history of, 225  
 obsessive-compulsive disorder, 204–206, 208–209, 216, 225–231

- Cingulotomy (*continued*)  
 SPECT in, 238–249  
 patient selection for, 227–228, 231  
 physiologic considerations in, 225–227  
 results of, 228–231, 241–243  
 technique for, 228, 239  
 versus alternative surgical methods, 231–233
- Cisterna magna, enlargement of, 615
- Clear cell ependymoma, 473, 478, 573
- Clivus  
 exposure of, in pituitary surgery, 101–102  
 neoplasms of, imaging of, 76–78
- Clonidine, intrathecal delivery of, 360, 384
- Coccydynia, spinal cord stimulation for, 378
- Colloid cyst, 552–554, 609
- Colorectal cancer  
 in acromegaly, 45  
 intraventricular metastasis from, 596–597
- Compensation systems, pain management and, 341, 349–350
- Complex regional pain syndrome, spinal cord stimulation for, 378
- Computed tomography  
 in choroid plexus tumors, 624  
 in colloid cyst, 609  
 in craniopharyngioma, 62–63  
 in empty sella syndrome, 64–65  
 in ependymoma, 572  
 in hypothalamic astrocytoma, 65–66  
 in intraventricular meningioma, 561  
 in lateral ventricle tumors, 514  
 in meningioma, 67  
 in neurocytoma, 484  
 in pituitary abscess, 71  
 in pituitary adenoma, 59  
 in schwannoma, 70  
 in subependymal giant cell astrocytoma, 584  
 in subependymoma, 579  
 in suprasellar aneurysm, 75  
 in third ventricular tumors, 528
- Congenital intraventricular lesions, **607–619**  
 arachnoid cyst, 63–64, 609–611  
 choroid plexus cyst, 611–612  
 colloid cyst, 552–554, 609  
 corpus callosum lipoma, 615  
 Dandy-Walker malformation, 613–615  
 embryology of, 607–608  
 ependymal cyst, 612  
 epidermoid cyst, 613  
 neurenteric cyst, 613  
 pineal cyst, 612–613  
 tuberous sclerosis, 615–617  
 versus normal variants, 608–609
- Conus medullaris compression, in intrathecal medication delivery, 358
- Cordotomy, for pain, 328
- Corpus callosum, lipoma of, 615
- Corticosteroids, for hypopituitarism, after pituitary surgery, 129
- Corticostriothalamocortical circuitry  
 in depression, 216–219  
 in obsessive-compulsive disorder, 214, 218–219
- Corticotroph(s), 25
- Corticotroph adenoma  
 Cushing's disease in, 45–48  
 diagnosis of, 169  
 long-term management of, 169  
 outcome of, 169  
 medical treatment of, 142  
 pathology of, 31–32  
 persistent, 141–142  
 radiotherapy for, 142  
 silent, 32  
 surgical treatment of, 169  
 persistent, 141–142  
 postoperative endocrine management in, 130–131, 133–134  
 preoperative management in, 94
- Corticotropin, 18–19, 25  
 adenomas secreting. *See* Corticotroph adenoma.  
 deficiency of, after pituitary surgery, 132–133  
 measurement of, in corticotroph adenoma, 47
- Corticotropin-releasing hormone stimulation test, in corticotroph adenoma, 47
- Cortisol  
 excess of, in corticotroph adenoma, 31–32, 45–48  
 medical treatment of, 83–84  
 persistent, 141–142  
 preoperative management of, in pituitary tumors, 94
- Cranial nerve dysfunction, after pituitary radiotherapy, 162
- Craniopharyngioma. *See also* Third ventricular tumors.  
 imaging of, 61–63

Cre-lox system, for gene transfer, for pain management, 422

Cushing, Harvey, transsphenoidal approach of, 2–5, 7

Cushing's disease  
 after pituitary surgery, 130–131, 133–134  
 in corticotroph adenoma, 31–32, 45–48  
 long-term management of, 169  
 outcome of, 169  
 persistent, 141–142  
 medical treatment of, 83–84

CyberKnife, for neurocytoma, 501

Cyst(s)  
 arachnoid  
   intraventricular, 63–64  
   parasellar, 63–64  
 choroid plexus, 611–612  
 colloid, 552–554, 609  
 ependymal, 612  
 epidermoid  
   intraventricular, 613  
   parasellar, 64  
 neurenteric, 613  
 parasellar, imaging of, 63–64  
 pineal, 612–613  
 Rathke's cleft, 63

Cystitis, interstitial, peripheral nerve stimulation for, 377

Cytokeratins, in choroid plexus tumors, 470

Cytomegalovirus, for gene transfer, for pain management, 422

## D

Dandy Walker malformation, 613–615

Deep brain stimulation, **389–399**  
 complications of, 395–396  
 for neuropathic pain, 390–391  
 for nociceptive pain, 391  
 history of, 332–334, 389–390  
 mechanism of action for, 390–391  
 off-label use of, 396  
 patient selection for, 391–392  
 physiology of, 454–455  
 preoperative evaluation for, 391–392  
 rationale for, 390–391  
 results of, 394–396  
 target site selection for, 392  
 technique for, 392–394  
 tolerance to, 395

Delgado, Jose M.R., on psychiatric neurosurgery, 309

Deniker, Pierre, psychoactive drug therapy discovery by, 190

Depression, **199–212**  
 clinical features of, 201  
 epidemiology of, 201  
 evaluation of, before pain management, 411–412, 414–415  
 medical treatment of, 201  
 neurocircuitry models for, 216–219  
 neuroimaging in, 216–219  
 neurosurgery for  
   capsulotomy, 219, 232–233  
   cingulotomy, 204–206, 208–209, 225–228  
   current awareness of, 201–202  
   effectiveness of, 207–209  
   history of, 202–203  
   limbic leukotomy, 205–207, 209, 232  
   modern procedures for, 203–205  
   neuroimaging and neurocircuitry related to, 218–219  
   safety of, 205–207  
   subcaudate tractotomy, 204–205, 207, 218, 231  
 thalamocortical dysrhythmia in. *See* Thalamocortical dysrhythmia.  
 transcranial magnetic stimulation for, 288–293  
   maintenance, 292  
   meta-analysis of, 289–292  
   with intentional seizure generation, 294–295  
 treatment of, before pain management, 348  
 vagus nerve stimulation for, **275–282**

Desmopressin (DDAVP), for diabetes insipidus, after pituitary surgery, 126, 132

Dexamethasone suppression test, in corticotroph adenoma, 47

Diabetes insipidus, after pituitary surgery, 124–126, 132

Diabetic neuropathy, pain in  
 gene therapy for, 430  
 spinal cord stimulation for, 378

Diaphragma sellae, anatomy of, 16

Diethelm, Oskar, on ethics of neuropsychiatric surgery, 305–307

Dizziness, in neurocytoma, 483

DNA, in gene therapy, for pain, 420–421, 427–430

Dopamine, deficiency of, gene therapy for, 426

- Dopamine agonists
  - for gonadotroph adenoma, 84
  - for prolactinoma, 30–31, 81–82, 89–90, 143
- Dott, Norman, transsphenoidal approach of, 5–7
- Dynorphin, in antinociception, 453

## E

---

- Edema, in intrathecal morphine delivery, 385–386
- Electrical stimulation
  - deep brain, 332–334, **389–399**
  - implantable stimulators for, 331–334, 372–375, 403–406
  - internal capsule anterior limb, for obsessive-compulsive disorder, **267–274**
  - motor cortex, 334
  - peripheral nerve, 331, **401–408**
  - precentral, 334, **437–443**
  - spinal cord, 331–332, **365–380**
  - vagus nerve, for depression, **275–282**
- Electroconvulsive therapy, for psychiatric disorders, 184, 201
  - versus transcranial magnetic stimulation, 287–289, 291–292, 294
- Electroencephalography, in depression, in vagus nerve stimulation, 280
- Electropermeabilization, in gene therapy, for pain, 420
- Eloquent cortex, localization of, transcranial magnetic stimulation for, 287
- Empty sella syndrome, 16, 64–65
- Endocrinopathies, in pituitary tumors. *See* Pituitary tumors, endocrinopathies in.
- Endometriosis, pain in, gene therapy for, 430–431
- Endonasal transsphenoidal approach, to pituitary tumors, 99–100
  - lateral (Hirsch), 1–2
- Endoscopy
  - in intraventricular surgery, **547–557**
    - anatomic considerations in, 548–549
    - colloid cyst resection, 552–554
    - equipment for, 549–551
    - history of, 547–548
    - pineal tumor management, 554–555
    - two-portal, 551
    - ventriculostomy, 551–552
  - in transsphenoid approach, to pituitary tumors, 104–105
- Enkephalins, in antinociception, 453
- Ependymal cyst, 612
- Ependymoma
  - classification of, 572–573
  - intraventricular, 571–578
    - anaplastic, 573
    - cellular, 573
    - clear cell, 473, 478, 573
    - clinical presentation of, 572
    - differential diagnosis of, 474
    - epidemiology of, 472, 571–572
    - genetic features of, 474
    - imaging of, 572
    - infratentorial, 574–576
    - papillary, versus choroid plexus tumors, 472
    - pathology of, 470–474, 572–574
    - prognosis of, 577–578
    - supratentorial, 574–576
    - tanycytic, 573
    - third ventricular. *See* Third ventricular tumors.
    - treatment of, 574–578
    - versus central neurocytoma, 478
    - versus subependymoma, 475
- Epidermoid cyst
  - intraventricular, 613
  - parasellar, 64
- Epidermoid tumors, in third ventricle. *See* Third ventricular tumors.
- Epilepsy
  - transcranial magnetic stimulation for, 286–287, 293
  - vagus nerve stimulation for, 276–277
- Epithelial membrane antigen, in choroid plexus tumors, 470
- Equine infectious anemia virus, for gene transfer, for pain management, 425
- Ervin, Frank R., on psychiatric neurosurgery, 309
- Estrogen, for persistent prolactinoma, 142
- Ethical issues, in neuropsychiatric surgery, **303–319**
  - historical aspects of, 303–308
  - regulatory aspects of, 312–315
  - sociopolitical aspects of, 308–312

## F

---

- Federal Employees' Compensation Act, 349
- Federal Employers' Liability Act, 349

- Feline immunodeficiency virus, for gene transfer, for pain management, 425
- Fiamberti, Amaro, transorbital lobotomy procedure of, 189
- Fluid restriction, in antidiuretic hormone inappropriate secretion, 128–129
- Follicle stimulating hormone, 19, 25–26  
excess of, in gonadotroph adenoma, 34, 42–43, 84
- Foramen of Monro, anatomy of, 510–511
- Foreign body reactions, in deep brain stimulation, 395
- Fornices, anatomy of  
in endoscopic surgery, 548  
in third ventricular surgery, 531
- Fourth ventricle, dilation of, in Dandy Walker malformation, 613–615
- Freeman, Walter, psychiatric neurosurgical procedures of, 182–183, 185–190, 303–306
- Frontal horn, anatomy of, 510–511
- Frontal lobotomy, history of, 182–190, 203, 303–308
- Frontal transcortical (middle frontal gyrus) approach, to lateral ventricle tumors, 517–518
- Frontotemporal transcavernous approaches, to parasellar and parasellar lesions, 109–121  
bifrontal transbasal, 114–119  
orbitozygomatic, 109–114  
pterional, 109–111  
supraorbital, 119–121  
transzygomatic, 109–111
- Fulton, John F., neurophysiologic studies of, 182, 185–187
- Functional neuroimaging, in  
obsessive-compulsive disorder, 215
- Furosemide, for antidiuretic hormone inappropriate secretion, 129
- G**
- $\alpha$ -Galactosidase A deficiency, pain in, gene therapy for, 431
- Gall, Franz Joseph, on phrenology, 181
- Gamma-aminobutyric acid  
deficiency of, gene therapy for, 426  
receptors for, in antinociception, 453–454
- Gamma knife capsulotomy, for psychiatric disorders, 204–208
- Gamma knife radiosurgery  
for neurocytoma, 498, 501  
for pituitary tumors, 156–161  
for somatotroph adenoma, 83
- Ganglioneurocytoma, 477
- Gasserian ganglion, in nociception, 446–447
- Gate theory of pain, 328–331, 451
- Gemistocyte-like cells, in subependymal giant cell astrocytoma, 475–476
- Gene-gun method, for gene transfer, 428
- Gene therapy, for pain, **419–435**  
advantages of, 419, 422  
cell lines for, 429–430  
complications of, 430  
ex vivo, 429–430  
neuromodulation, 425–429  
nonviral, 420–421  
root causes, 429–430  
viral vectors in, 421–425
- Germinoma, parasellar, imaging of, 71
- Giant cell astrocytoma, subependymal, 470–471, 475–476, 584–585
- Glial-derived neurotrophic factor, in nociception, 446
- Glial fibrillary acidic protein  
for gene transfer, for pain management, 422  
in choroid plexus tumors, 470  
in ependymoma, 473  
in subependymal giant cell astrocytoma, 585
- Glioma. *See also* Ependymoma;  
Subependymoma.  
intraventricular  
choroid, 585–586  
subependymal giant cell astrocytoma, 470–471, 475–476, 584–585  
types of, 571  
parasellar, after pituitary radiotherapy, 162
- Glutamate, in pain transmission, 451–452
- Glutamate decarboxylase deficiency, gene therapy for, 426
- Glycine, intrathecal delivery of, 360
- Goltz, Friedrich, temporal lobotomy procedure of, 181
- Gonadotroph(s), 25–26

Gonadotroph adenoma  
 diagnosis of, 42–43  
 endocrinopathy in, 42–43  
 imaging of, 43  
 medical treatment of, 84  
 pathology of, 34

Gonadotropins, 19, 25–26  
 adenoma secreting. *See* Gonadotroph adenoma.  
 deficiency of, after pituitary surgery, 132–133

Grant, Francis, lobotomies by, 186

Granuloma, at catheter tip, in intrathecal drug delivery, 386

Graves' disease, in thyrotroph adenoma, 49

Grinker, Roy, on ethics of neuropsychiatric surgery, 306–307

Growth hormone, 19–20, 25  
 deficiency of, after pituitary surgery, 133  
 pituitary tumors secreting. *See* Somatotroph adenoma.

Growth hormone-releasing hormone, 20

Guiot, Gerard, transsphenoidal approach of, 6, 8

---

**H**

Hallucinations, thalamocortical dysrhythmia in.  
*See* Thalamocortical dysrhythmia.

Hardy, Jules, transsphenoidal approach of, 8–10

Headache  
 in deep brain stimulation, 396  
 in intraventricular metastasis, 595  
 in lateral ventricle tumors, 510  
 in neurocytoma, 483  
 peripheral nerve stimulation for, 404–405

Hemangiopericytoma, parasellar, imaging of, 68–70

Hemianopsia, bitemporal, in prolactinoma, 29

Hemiparesis, in lateral ventricle tumor surgery, 523

Hemorrhage, intracranial  
 in deep brain stimulation, 395  
 in intraventricular metastasis, 595  
 in lateral ventricle tumor surgery, 523  
 in third ventricular tumor surgery, 542

Herniorrhaphy, postoperative pain in, peripheral nerve stimulation for, 406

Herpes simplex virus 1, for gene transfer, for pain management, 424–425, 428–429

Hippocampus, connections to, in depression, 216–218

Hirsch, Oscar, transsphenoidal approach of, 1–2

Histiocytosis X, of pituitary, 72, 74

Hormones, pituitary, 17–22, 25–26. *See also specific hormones.*  
 abnormalities of. *See* Pituitary tumors, endocrinopathies in.

Human chorionic gonadotropin, in third ventricular tumors, 528

Human immunodeficiency virus, for gene transfer, for pain management, 425

Hydrocephalus  
 after lateral ventricle tumor removal, 523  
 after third ventricular tumor removal, 542  
 endoscopic ventriculostomy for, 551–552  
 in choroid plexus tumors, 623–626  
 in Dandy Walker malformation, 613–615  
 in ependymoma, 572, 574  
 in lateral ventricle tumors, 509  
 in subependymal giant cell astrocytoma, 584  
 in subependymoma, 579  
 in third ventricular tumors, 528

Hydrocortisone, for hypopituitarism, after pituitary surgery, 129

Hyperalgesia  
 central mechanisms of, 450–451  
 in gene therapy for pain, 431

Hypercortisolemia, in corticotroph adenoma, 31–32, 45–48  
 medical treatment of, 83–84  
 persistent, 141–142

Hypernatremia, after pituitary surgery, 124–126

Hyperprolactinemia  
 in acromegaly, 44  
 in prolactinoma, 29–31, 41–42  
 medical treatment of, 81–82  
 persistent, 142–143

Hyperthyroidism, in thyrotroph adenoma, 48–50

Hypocortisolism, after pituitary surgery, 129–130

Hypogonadism  
 in gonadotroph adenoma, 42  
 in prolactinoma, 81–82

Hyponatremia, after pituitary surgery, 126–129



Hypophyseal arteries, anatomy of, 14–15

Hypophysectomy, in persistent acromegaly, 140

Hypophysis. *See* Pituitary gland; Pituitary tumors.

Hypopituitarism  
 after pituitary surgery, 129–130  
 in gonadotroph adenoma, 42  
 in somatotroph adenoma, 44

Hypothalamic-pituitary-adrenal axis, connections to, in depression, 216

Hypothalamus  
 anatomy of, in third ventricular surgery, 529  
 astrocytoma of, imaging of, 65–66  
 dysfunction of, after pituitary radiotherapy, 161–162

Hypoxanthine-guanine phosphoribosyltransferase gene transfer, 422–423

## I

Immunohistochemistry  
 in choroid plexus tumors, 470, 623  
 in ependymoma, 473  
 in neurocytoma, 485  
 in subependymoma, 582

Implantable devices, for pain management  
 electrical stimulation, 331–334, 372–375  
 peripheral nerve, 403–406  
 spinal cord, 372–375  
 intrathecal drug delivery, 331–334, 372–375

Impulse control disorder, thalamocortical dysrhythmia in. *See* Thalamocortical dysrhythmia.

Incisural space, posterior, anatomy of, in third ventricular surgery, 531

Infections  
 in deep brain stimulation, 395  
 in intrathecal medication delivery, 357  
 in spinal cord stimulation, 375–376

Inferior petrosal sinus sampling, in corticotroph adenoma, 47–48

Inflammation, at catheter tip, in intrathecal drug delivery, 386

Infratentorial supracerebellar approach  
 to intraventricular meningioma, 566  
 to third ventricular tumors, 532–538

Infundibulum, in pituitary embryogenesis, 11–12

Inguinal pain, peripheral nerve stimulation for, 406

Inositol triphosphate, in pain transmission, 452

Institutional review boards, for psychiatric neurosurgery research, 313

Insula, in nociception, 448

Insulin-like growth factor-1, in somatotroph adenoma, 139–141

Insulin resistance, in acromegaly, 44

Interhemispheric approaches  
 to intraventricular meningioma, 565–566  
 to lateral ventricle tumors, 520–522

Interhemispheric-transcallosal approach, to third ventricular tumors, 532, 534, 538–539

Interleukin-12 gene transfer, for pain, 427–428

Intermediate filaments, in subependymal giant cell astrocytoma, 476

Intermediate lobe, pituitary, physiology of, 20–21

Intracranial pressure, increased  
 in choroid plexus tumors, 623–624  
 in ependymoma, 572  
 in intraventricular metastasis, 595  
 in lateral ventricle tumors, 510  
 in neurocytoma, 483

Intrathecal pain management, **353–363**  
 complications of, 358–359  
 contraindications to, 355  
 delivery of, **381–387**  
 clinical studies of, 383–385  
 inflammatory mass interference with, 386  
 pharmacodynamics of, 381–383  
 side effects of, 385–386  
 sites for, 354  
 devices for  
 evaluation of, 358  
 failure of, 358  
 implantation of, 357–358  
 management of, 359  
 replacement of, 359  
 selection of, 355–357  
 dose changes in, 359  
 drugs used in, 360–361  
 future of, 360–362  
 history of, 353–354  
 intraventricular route of, 354, 356  
 outcomes of, 359–360  
 patient selection for, 354–355  
 psychologic variables in, 410–412

Intrathecal (*continued*)

- trial of, 355
- versus epidural delivery, 354
- versus medical treatment, 383

## Intraventricular tumors

- choroid plexus, 469–472, **621–631**
- congenital, **607–619**
- differential diagnosis of, 469
- ependymoma. *See* Ependymoma.
- epidemiology of, **469–482**. *See also specific tumor types.*
- glioma, **571–591**
- lateral, **509–525**
- meningioma, 470–471, **559–569**
  - of third ventricle. *See* Third ventricular tumors.
- metastatic, **593–606**
- neurocytoma, 470–471, 476–478, **483–508**
- pathology of, **469–482**
- posterior, **527–545**
- subependymal giant cell astrocytoma, 470–471, 475–476, 584–585
- subependymoma. *See* Subependymoma.
- surgical treatment of, endoscopic adjuncts to, **547–557**

Irrigation, in endoscopic intraventricular surgery, 550–551

**J**

Jacobsen, Carlyle, neurophysiologic studies of, 182

**K**

Kainate receptors, in pain transmission, 451

Kelly, Desmond, limbic leukotomy procedure of, 193

Ketamine, intrathecal delivery of, 360

Ketoconazole, for Cushing's disease, 83–84, 142

Ki-67 antigen

- in choroid plexus tumors, 470
- in ependymoma, 473

Knight subcaudate tractotomy, 193

**L**

Laborit, Henri, psychoactive drug therapy discovery by, 190

Lactotroph(s), 25. *See also* Prolactin; Prolactinoma.

Laminotomy, for spinal cord stimulation implant, 375

## Lanreotide

- for somatotroph adenoma, 83, 140
- for thyrotroph adenoma, 84

Lateral ventricles, tumors of, **509–525**

- anatomic considerations in, 510–514
- blood supply of, 513–514
- clinical presentations of, 509–510
- differential diagnosis of, 510
- epidemiology of, 509–510
- intraoperative considerations in, 514–516
- outcome of, 522–524
- postoperative considerations in, 516, 522–524
- preoperative considerations in, 514
- surgical approaches to, 516–522
  - frontal transcortical (middle frontal gyrus), 517–518
  - interhemispheric, 520–522
  - parietal transcortical (superior parietal lobule), 519–520
  - temporal transcortical (middle temporal gyrus), 518–519
- types of, 509

Leksell, Lars, capsulotomy procedure of, 191

Lentiviruses, for gene transfer, for pain management, 425

## Leukotomy

- limbic, for psychiatric disorders, 193
  - depression, 205–207, 209, 232
  - obsessive-compulsive disorders, 205–207, 209, 218–219, 232
  - versus cingulotomy, 232
- orbitomedial, for obsessive-compulsive disorder, 218

Li-Fraumeni syndrome, choroid plexus tumors in, 472

Lima, Almeida, early frontal lobotomies by, 182

Limbic leukotomy, for psychiatric disorders, 193
 

- depression, 205–207, 209, 232
- obsessive-compulsive disorders, 205–207, 209, 218–219, 232

Limbic system, in psychiatric disorders
 

- dysfunction of, 226
- pathway disruption in. *See* Cingulotomy; Limbic leukotomy.

Linear accelerator-based radiosurgery
 

- for neurocytoma, 501
- for pituitary tumors, 155–156

Lipoma, of corpus callosum, 615

Liposome-mediated gene transfer, for pain, 421

Lobotomy  
     frontal, history of, 182–190, 203, 303–308  
     prefrontal, history of, 182–190  
     transorbital, 189

Long Shore and Harbor Workers' Act, 349

Lung carcinoma, intraventricular metastasis from, 596–597

Luteinizing hormone, 19, 25–26  
     excess of, in gonadotroph adenoma, 34, 42–43, 84

Lyerly, James, psychiatric neurosurgical procedures of, 186–187

Lymphocytic adenohypophysitis, imaging in, 72–73, 75

Lymphoma, clival, imaging of, 78

Lysosomes, in subependymal giant cell astrocytoma, 476

## M

Macroadenoma, pituitary, imaging of, 59–60

Macrostimulation, in deep brain stimulation, 393

Magnetic resonance imaging  
     blood oxygenation level-dependent  
         in depression, in vagus nerve stimulation, 279  
     in transcranial magnetic stimulation studies, 288  
     in arachnoid cyst, 64  
     in choroid plexus tumors, 624, 626  
     in colloid cyst, 609  
     in craniopharyngioma, 63  
     in deep brain stimulation, 392–393  
     in empty sella syndrome, 64–65  
     in ependymal cyst, 612–613  
     in ependymoma, 572  
     in epidermoid cyst, 64  
     in germinoma, 71  
     in hemangiopericytoma, 69–70  
     in histiocytosis, 74  
     in hypothalamic astrocytoma, 66  
     in lateral ventricle tumors, 514  
     in lymphocytic adenohypophysitis, 73, 75  
     in meningioma, 67–68, 561, 564  
     in metastatic intraventricular tumors, 594  
     in neurocytoma, 484  
     in pituitary abscess, 71  
     in pituitary histiocytosis X, 72  
     in pituitary tuberculosis, 71  
     in pituitary tumors, 57–61, 94

    corticotroph, 47  
     for radiotherapy planning, 151–152  
     for stereotactic radiosurgery, 160  
     gonadotroph, 43  
     preoperative, 94  
     prolactinoma, 42  
     in precentral stimulation, 438  
     in Rathke's cleft cyst, 63  
     in schwannoma, 70  
     in stereotactic cingulotomy, 228, 238  
     in subependymal giant cell astrocytoma, 584  
     in subependymoma, 579  
     in suprasellar aneurysm, 76  
     in third ventricular tumors, 528  
     morphometric  
         in depression, 217  
         in obsessive-compulsive disorder, 214

Magnetic resonance spectroscopy  
     in neurocytoma, 484  
     in obsessive-compulsive disorder, 214–215

Magnetic stimulation, transcranial. *See* Transcranial magnetic stimulation.

Magnetoencephalography, in thalamocortical dysrhythmia, 253–256, 260

Mammillary bodies, anatomy of, in endoscopic surgery, 548–549

Mammosomatotroph adenoma, 27–28

Manganese superoxide dismutase gene transfer, for pain management, 430

Mania, transcranial magnetic stimulation for, 292

Mark, Vernon H., on psychiatric neurosurgery, 309–310, 315

Mearns, Edward, on psychiatric neurosurgery, 311–313

Medical history, in pain management, review of, 340–342

Melanotropins, 20–21

Melzack-Wall gate theory of pain, 328–331, 451

Memory loss, in lateral ventricle tumor surgery, 523

Meningioma

    intraventricular, 478, **559–569**  
         anatomic considerations in, 559–560  
         clinical presentation of, 560–561  
         incidence of, 559  
         origin of, 559–560  
         pathology of, 560

Meningioma (*continued*)

- radiography in, 561–562
- treatment of, 561–568
  - observation in, 561, 563
  - options for, 561, 563
  - radiosurgery in, 563
  - radiotherapy in, 563
  - surgical, 563–568

parasellar, imaging of, 67–68

Meningitis, in intrathecal medication delivery, 357–358

Mental status alterations, in neurocytoma, 483

## Metastasis

- intraventricular, 478, **593–606**
  - assessment of, 599–600
  - classification of, 593
  - clinical presentation of, 594–598
  - diagnosis of, 594–595
  - histology of, 595–598, 602–603
  - incidence of, 593–594
  - location of, 595–598
  - metachronous presentation of, 594–595
  - multiple, 602
  - outcome of, 604
  - radiography in, 600–602
  - single, 600–602
  - surgical treatment of, 598–604
  - synchronous presentation of, 594–595
- to clivus, imaging of, 78
- to pituitary, imaging of, 71

*N*-Methyl-D-aspartate (NMDA) receptors, in pain transmission, 451–453

antagonists of, 360

Metyrapone, for Cushing's disease, 83–84

## Microadenoma, pituitary

- imaging of, 59
- surgical treatment of, **89–92**

Microlumina, in ependymoma, 473

Microscopy, in neurocytoma, 485

Microvilli, in choroid plexus tumors, 470–471

Middle temporal gyrus approach, to intraventricular meningioma, 564–565

Midline suboccipital approach, to intraventricular meningioma, 566, 568

Midnight plasma cortisol measurement, in corticotroph adenoma, 47

Mitotane, for Cushing's disease, 142

Mixer, W. Jason, lobotomies by, 187

MK-801, intrathecal delivery of, 360

Moniz, Egas, psychiatric neurosurgical procedures of, 182–183, 185–186, 190, 305–306

Morphine, intrathecal delivery of, 354, 358, 360
 

- clinical studies of, 383–385
- pharmacodynamics of, 381–383
- side effects of, 385–386

Morphine-naloxone test, for deep brain stimulation preoperative evaluation, 391–392

Mortality, in lateral ventricle tumor surgery, 523

Motivation, evaluation of, before pain management, 415

Motor cortex, stimulation of, 334, **437–443**

- complications of, 441
- indications for, 438
- literature review on, 439–441
- mechanism of, 437–438
- technique for, 438–439

Motor disorders, in lateral ventricle tumors, 510

Movement disorders, transcranial magnetic stimulation for, 293

Myoclonus, in intrathecal morphine delivery, 385–386

---

**N**

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, psychiatric neurosurgery and, 312–314, 316

National Psychosurgery Advisory Board, 313–315

Nausea and vomiting, in lateral ventricle tumors, 510

Nelson's syndrome, in corticotroph adenoma, 31–32

Nerve(s), injury of, peripheral sensitization in, 449

Nerve fibers, sensory, physiology of, 445

Neural crest, congenital lesions developing from, 607–608

Neuralgia, occipital, peripheral nerve stimulation for, 377–378

Neurenteric cyst, 613

Neuroaugmentation. *See also specific techniques.*

- definition of, 327
- evaluation for, **339–352**
- history of, **327–337**

- deep brain stimulation, 332–334
    - early theories on, 327–328
    - gate theory, 328–331
    - motor cortex stimulation, 334
    - peripheral nerve stimulation, 331
    - spinal cord stimulation, 331–332
    - psychologic evaluation for, **409–417**
  - Neurocircuitry models, for psychiatric disorders, **213–223**
    - depression, 216–219
    - obsessive-compulsive disorder, 214–216, 218–219
  - Neurocytoma, intraventricular, **483–508**
    - atypical, 486–487
    - clinical presentation of, 483
    - epidemiology of, 476–477, 483
    - genetic features of, 477–478
    - imaging of, 484
    - pathology of, 477–478, 484–487
    - recurrent, treatment of, 494, 497–498
    - stereotactic biopsy in, 494
    - treatment of, 487–504
      - acute, 492
      - chemotherapy in, 487, 501–503
      - follow-up in, 503–504
      - observation, 492
      - overview of, 487–492
      - paradigm for, 504
      - radiation therapy in, 487–491, 493–501
      - recurrent, 494, 497–498
      - surgical, 487–494
    - versus ependymoma, 472
  - Neuroendoscopy. *See* Endoscopy.
  - Neurohypophysis
    - anatomy of, 55–56
    - histology of, 21
    - hormones of, 21–22
    - vascular anatomy of, 15
  - Neuroimaging. *See also specific techniques.*
    - for psychiatric disorders, **213–223**
      - depression, 216–219
      - obsessive-compulsive disorder, 214–216, 218–219
  - Neuroma, peripheral sensitization in, 449–450
  - Neuronal specific enolase
    - for gene transfer, for pain management, 422
    - in central neurocytoma, 477
    - in neurocytoma, 485
  - Neuropathic pain
    - deep brain stimulation for, 390–392, 394
    - spinal cord stimulation for, 378
  - Neuropeptide FF, in antinociception, 453
  - Neuropeptide Y, in antinociception, 453–454
  - Neurotrophic growth factors, in peripheral sensitization, 449–450
  - Neville, Robert, on psychiatric neurosurgery, 312
  - Nitric oxide, in peripheral sensitization, 450
  - NMDA (*N*-methyl-D-aspartate) receptors, in pain transmission, 451–453
    - antagonists of, intrathecal delivery of, 360
  - Nociception
    - anatomy of, 445–448
    - receptors in, 448–449
  - Nociceptive pain, deep brain stimulation for, 391–392, 395
  - Nonfunctioning or nonsecreting pituitary tumors. *See* Pituitary tumors, nonfunctioning.
  - Nonsteroidal anti-inflammatory drugs, for diabetes insipidus, 132
  - Norepinephrine, in nociception, 455
  - Nose, pituitary surgical approach through, 1–2, 99–100
  - Nucleus raphe magnus, in nociception, 454–455
  - Nucleus ventralis posteriomedialis, electrical stimulation of, 389, 391–393
  - Null cell adenoma, pathology of, 34–35
- ## O
- 
- Obesity, pain management and, 342
  - Obsessive-compulsive disorder, **199–212**
    - behavioral therapy for, 200–201
    - clinical features of, 200
    - diagnosis of, SPECT in, 238, 241–242
    - epidemiology of, 200
    - medical treatment of, 200
    - neurocircuitry models for, 214–216, 218–219
    - neuroimaging in, 214–216, 218–219
    - neurosurgery for
      - capsule anterior limb electrical stimulation, **267–274**
      - capsulotomy, 204–208, 219, 232–233
      - cingulotomy, 204–206, 208–209, 216, 225–231, 238–249
      - current awareness of, 201–202
      - effectiveness of, 207–209
      - history of, 202–203

Obsessive-compulsive (*continued*)

- limbic leukotomy, 205–207, 209, 218–219, 232
  - modern procedures for, 203–205
  - neuroimaging and neurocircuitry related to, 218–219
  - safety of, 205–207
  - subcaudate tractotomy, 204–205, 207, 218, 231–232
  - pathophysiology of, 226
  - positron emission tomography in, 226, 246–248
  - SPECT in, **237–250**
    - diagnostic, 238, 241–242
    - postoperative, 238–241, 245–249
  - thalamocortical dysrhythmia in. *See* Thalamocortical dysrhythmia.
  - transcranial magnetic stimulation for, 293–294
- Occipital headache, peripheral nerve stimulation for, 377–378, 404–405
- Occipital transtentorial approach
- to intraventricular meningioma, 566
  - to third ventricular tumors, 532, 539–541
- OCD. *See* Obsessive-compulsive disorder.
- Octreotide
- for gonadotroph adenoma, 84
  - for somatotroph adenoma, 83, 140
  - for thyrotroph adenoma, 84
  - intrathecal delivery of, 361
- Oligodendroglioma
- versus central neurocytoma, 478
  - versus ependymoma, 472
- Oncocytoma, pituitary, pathology of, 35
- Opioids. *See also* Morphine.
- endogenous, in antinociception, 453
  - intrathecal delivery of, 354, 358
- Optic chiasm, anatomy of, pituitary surgery and, 17
- Optic nerve, anatomy of, pituitary surgery and, 17
- Orbitofrontal-subcortical connections
- in depression, 216–219
  - in obsessive-compulsive disorder, 214, 218–219
  - interruption of, in subcaudate tractotomy, 193, 204–205, 207
- Orbitomedial leukotomy, for obsessive-compulsive disorder, neuroimaging in, 218
- Orbitozygomatic approach, to parasellar and suprasellar lesions, 109–114
- Oxytocin, 21–22

**P**

- Pain, chronic, anatomy and physiology of, **445–462**
- antinociception, 452–454
  - central sensitization, 450–452
  - descending systems, 454–455
  - nociception, 445–448
  - peripheral sensitization, 449–450
  - supraspinal plasticity, 455
  - supraspinal systems, 454–454
- Pain evaluation, **339–352**
- compensation systems and, 341, 349–350
  - for patient selection, 339–340
  - medical history review in, 340–342
  - physical findings in, 342–343
  - prior treatment evaluation, 345–347
  - psychologic report review in, 343–345
  - psychosocial issues in, 347–348
  - secondary gain and, 349
- Pain management
- anatomic and physiologic considerations in, **445–462**
  - compliance with, 343, 345
  - decision not to treat, 340
  - deep brain stimulation for, **389–399**
  - evaluation for, **339–352**
  - failure of, 339–340, 345
    - in spinal cord stimulation, 377, 410
  - gene therapy for, **419–435**
  - intrathecal medications for. *See* Intrathecal pain management.
  - neuroaugmentation for
    - evaluation for, **339–352**
    - history of, **327–337**
    - psychologic evaluation for, **409–417**
  - pain classification for, 329–330
  - peripheral nerve stimulation for. *See* Peripheral nerve stimulation.
  - precentral stimulation for, 334, **437–443**
  - regression of benefit in, 339–340, 345
  - spinal cord stimulation in. *See* Spinal cord stimulation.
  - terminology of, 329–330
- Paleospinothalamic tract, in nociception, 447
- Palliative care, for psychiatric disorders, neurosurgery in, 316
- Pallidotomy, anterior medial, for thalamocortical dysrhythmia, 252–263
- magnetoencephalography with, 253–256, 260
  - patient selection for, 252
  - results of, 255, 259–263

- strategy for, 252–253, 259
- Papilledema, in lateral ventricle tumors, 510
- Papilloma, choroid plexus  
clinical features of, 623–624  
epidemiology of, 469, 621  
imaging of, 624, 626  
outcome of, 628–629  
pathology of, 469–472, 621–623  
treatment of, 624–627
- Paraplegia, in intrathecal drug delivery, 386
- Parasellar and suprasellar lesions. *See also*  
Pituitary tumors.  
anatomic considerations in, 16–17, 57  
imaging of  
anatomic considerations in, 55–57  
aneurysm, 75–76  
arachnoid cyst, 63–64  
clivus neoplasms, 76–78  
craniopharyngioma, 61–63  
empty sella, 64–65  
epidermoid cyst, 64  
germinoma, 71  
hemangiopericytoma, 68–70  
hypothalamic astrocytoma, 65–66  
meningioma, 67–68  
Rathke's cleft cyst, 63  
schwannoma, 70  
surgical treatment of  
bifrontal transbasal approach to, 114–119  
frontotemporal transcavernous approaches  
to, 109–121  
orbitozygomatic approach to, 109–114  
pterional approach to, 109–111  
supraorbital approach to, 119–121  
transcranial approaches to, **109–122**  
transzygomatic approach to, 109–111
- Paresthesia, in spinal cord stimulation, 372, 377
- Parietal occipital approach, superior, to  
intraventricular meningioma, 565
- Parietal transcortical (superior parietal lobule)  
approach, to lateral ventricle tumors, 519–520
- Parinaud's syndrome, in intraventricular  
meningioma, 561
- Parkinson's disease  
deep brain stimulation for, 315  
gene therapy for, 426  
transcranial magnetic stimulation for, 293
- Pediatric patients, choroid plexus tumors in,  
**621–631**
- carcinoma, 627–628  
clinical features of, 623–624  
epidemiology of, 621  
hydrocephalus in, 625–626  
imaging in, 624, 626  
outcome of, 628–629  
pathology of, 621–623  
treatment of, 624–628
- Pegvisomant, for acromegaly, 83, 140
- Pelvic pain, spinal cord stimulation for, 378
- Percutaneous implantation, for peripheral nerve  
stimulation, 403
- Pergolide, for prolactinoma, 81–82, 143
- Periaqueductal gray matter. *See* Deep brain  
stimulation.
- Perineurioma, intraventricular, 478
- Peripheral nerve stimulation, **401–408**  
complications of, 406  
for occipital headache, 404–405  
for postoperative inguinal pain, 406  
for supraorbital pain, 405  
history of, 331, 401  
indications for, 401  
mechanism of action of, 406–407  
open nerve dissection technique for, 402–403  
outcomes of, 407  
patient selection for, 401–402  
percutaneous implant technique for, 403  
spinal cord stimulation equipment for,  
377–378  
subcutaneous, 403–406  
techniques for, 402
- Peripheral sensitization, physiology of,  
449–450
- Periventricular gray matter, electrical stimulation  
of. *See* Deep brain stimulation.
- Phantom limb pain, physiology of, 452
- Phospholipase C, in pain transmission, 452
- Phrenology, 182
- Physical therapy, for pain, 340
- Pia mater, variants of, 609
- Pineal cyst, 612–613
- Pineal gland tumors. *See* Third ventricular  
tumors.
- Pituitary fossa, anatomy of, 15–16

## Pituitary gland

- abscess of, imaging in, 71
- anatomy of, 55–57
- dysfunction of, after pituitary radiotherapy, 161–162
- histiocytosis of, imaging in, 72, 74
- histogenesis of, 13
- histology of, 25–26
- hormones of, 17–22, 25–26. *See also specific hormones.*
  - abnormalities of. *See* Pituitary tumors, endocrinopathies in.
- hyperplasia of, imaging in, 61
- imaging of, 55–57. *See also* Pituitary tumors, imaging of.
  - abscess, 71
  - histiocytosis X, 72, 74
  - lymphocytic adenohypophysitis, 72–73, 75
  - sarcoidosis, 71
  - techniques for, 57
  - tuberculosis, 71
  - versus hyperplasia, 61
- lymphocytic adenohypophysitis of, 72–73, 75
- sarcoidosis of, imaging in, 71
- tuberculosis of, imaging in, 71
- tumors of. *See* Pituitary tumors.

## Pituitary tumors

- anatomic considerations in, **11–23**, 55–57
  - embryologic, 11–13
  - gross, 13–14
  - surgical, 15–17
  - vascular, 14–15
- carcinoma, pathology of, 36–37
- classification of, 25–26
- corticotropin-secreting. *See* Corticotroph adenoma.
- endocrinopathies in, **41–54**
  - acromegaly, 43–45, 82–83, 134, 139–141
  - Cushing's disease. *See* Cushing's disease, in corticotroph adenoma.
  - gonadotrophin abnormalities, 42–43
  - hyperprolactinemia, 29–31, 41–42, 81–82, 142–143
  - hyperthyroidism, 48–50
  - postoperative management of, **123–138**
    - acromegaly, 131, 133
    - antidiuretic hormone abnormalities, 123–129, 132
    - Cushing's disease, 130–131, 133–134
    - hypopituitarism, 129–130
    - in nonfunctioning tumors, 132–133
    - in prolactinoma, 131, 134
    - in somatotroph adenoma, 131, 133

- in thyrotroph adenoma, 131–132, 134
- gonadotrophin-secreting. *See* Gonadotroph adenoma.
- growth-hormone secreting. *See* Somatotroph adenoma.
- imaging of
  - adenoma, 57–61
  - corticotroph, 47
  - gonadotroph, 43
  - metastasis, 71
  - preoperative, 94
  - prolactinoma, 42
- long-term management of, **167–171**
- macroadenoma, 59–60
- malignant, after radiotherapy, 162
- medical treatment of, **81–87**, 140–144
  - in long-term management, **167–171**
  - in persistent endocrine activity, 140–144
- metastatic, imaging of, 71
- microadenoma, 59, **89–92**
- nonfunctioning
  - classification of, 169–170
  - long-term management of, 169–170
  - pathology of, 34–35
  - postoperative endocrine management in, 132–133
- null cell adenoma, 34–35
- oncocyoma, 34–35
- outcome of, **167–171**
- pathology of, **25–29**
  - carcinoma, 36–37
  - corticotroph adenoma, 31–32
  - gonadotroph adenoma, 34
  - nonfunctioning, 34–35
  - plurihormonal, 36
  - prolactinoma, 29–31
  - somatotroph adenoma, 26–29
  - thyrotroph adenoma, 32–33
  - versus normal pituitary, 25–26
- persistent functional, management of, **139–145**
- physiologic considerations in, 17–22
  - anterior lobe, 17–20
  - intermediate lobe, 20–21
  - posterior, 21–22
- plurihormonal, 28–29, 36
- prolactin-secreting. *See* Prolactinoma.
- radiation therapy for. *See* Radiation therapy, for pituitary tumors; Stereotactic radiosurgery, for pituitary tumors.
- surgical treatment of, **93–107**
  - bifrontal transbasal approach to, 114–119
  - frontotemporal transcavernous approaches to, 109–121



- in long-term management, 167–170
- in persistent endocrine activity, 139–143
- in suprasellar and parasellar region, **109–122**
- indications for, 93–94
- lateral endonasal approach (Hirsch) to, 1–2
- microprolactinoma, **89–92**
- nonfunctioning, 170
- orbitozygomatic approach to, 109–114
- postoperative endocrine management in, **123–145**
- preoperative considerations in, 94
- pterional approach to, 109–111
- stereotactic radiosurgery. *See* Stereotactic radiosurgery.
- sublabial transsphenoidal approach (Cushing) to, 2–4, 7
- supraorbital approach to, 119–121
- transcranial approaches to, 4–5, 103–104, **109–122**
- transsphenoidal approach to. *See* Transsphenoidal approach.
- transzygomatic approach to, 109–111
- thyrotropin-secreting. *See* Thyrotroph adenoma.
- treatment of
  - long-term, **167–171**
  - medical. *See* Pituitary tumors, medical treatment of.
  - microprolactinoma, **89–92**
  - persistent functional, **139–145**
  - radiation therapy. *See* Radiation therapy, for pituitary tumors.
  - surgical. *See* Pituitary tumors, surgical treatment of.
  - transsphenoidal approach to. *See* Transsphenoidal approach.
- versus hyperplasia, 61
- Plasmacytoma, clival, imaging of, 78
- Plasticity, supraspinal, in nociception, 455
- Pleomorphism, in central neurocytoma, 486–487
- Plurihormonal adenoma, 28–29, 36
- Polyethyleneimine, for gene transfer, 421
- Polyneuropathy, in acromegaly, 44
- Polyuria, in diabetes insipidus, after pituitary surgery, 125
- Positron emission tomography
  - in neurocytoma, 484
  - in obsessive-compulsive disorder, 226, 246–248
- Posterior commissure, anatomy of, in endoscopic surgery, 549
- Precentral stimulation, 334, **437–443**
  - complications of, 441
  - indications for, 438
  - literature review on, 439–441
  - mechanism of, 437–438
  - technique for, 438–439
  - trial stimulation in, 439
- Prefrontal lobotomy, history of, 182–190
- Pregnancy, in acromegaly, 45
- Preproenkephalin gene transfer, for pain management, 428–429
- Preprogalanin gene transfer, for pain management, 429
- Primary afferent depolarization, in antinociception, 453
- Prolactin, 20, 25
  - excess of. *See* Hyperprolactinemia.
  - in acidophilic stem cell adenoma, 27
  - in mammosomatotroph adenoma, 27–28
  - in somatotroph-lactotroph adenoma, 27
- Prolactinoma
  - diagnosis of, 42–43
  - differential diagnosis of, 42–43
  - endocrinopathy in, 42
  - hyperprolactinemia in, 29–31, 41–42
    - persistent, 142–143
    - treatment of, 81–82
  - imaging of, 42, 58
  - long-term management of, 167–168
  - medical treatment of, 81–82, 89–90, 143, 167
  - outcome of, 167–168
  - pathology of, 29–31
  - persistent, 142–143
  - radiotherapy for, 142
  - surgical treatment of, 90, 143
    - micro-, **89–92**
    - outcome of, 167–168
    - postoperative endocrine management in, 131, 134
- Proopiomelanocortin, 17, 20
- Proopiomelanocortin gene transfer, for pain, 427–428, 430
- Prostate hyperplasia, in acromegaly, 44
- Protein kinase C, in pain transmission, 452
- Proton beam radiosurgery, for pituitary tumors, 154–155

Pseudorosettes, in ependymoma, 472–473, 573

#### Psychiatric disorders

- evaluation of, before pain management, 411–412, 414–415
- in acromegaly, 45

Psychiatric neurosurgery. *See also specific procedures, e.g., Cingulotomy.*

for depression. *See* Depression, neurosurgery for.

for obsessive-compulsive disorder. *See* Obsessive-compulsive disorder, neurosurgery for.

for thalamocortical dysrhythmia, **251–265**

historical perspective of, **181–197**, 202–203

capsulotomy, 191–192

cingulotomy, 191–192

early years, 181–190

ethical aspects of, 303–308

future techniques derived from, 193–196

limbic leukotomy, 193

stereotactic methods, 190–193

subcaudate tractotomy, 193

neuroimaging and neurocircuitry models for, **213–223**

palliative, 316

research on

ethical considerations in, **303–319**

regulation of, 312–315

single-photon emission computed tomography in, **237–250**

sociopolitical aspects of, 308–312

transcranial magnetic stimulation, **283–301**

Psychologic evaluation, for neuroaugmentation, **409–417**

contraindications identified in, 413–414

drug administration, 410–412

factors in, 414–416

instruments for, 415–416

need for, 409–410

personnel for, 412

procedure for, 412–413

spinal cord stimulation, 410–412

Psychological issues, in pain management

deep brain stimulation with, 391

depression, 348, 411–412, 414–415

intrathecal, 354

personal relationships, 348

preoperative psychologic evaluation, **409–417**

psychologist report review, 343–345

return to work, 347–348

substance abuse, 348

#### Pterional approach

- to parasellar and suprasellar lesions, 109–111
- to pituitary tumors, 104

Pumps, for intrathecal pain management, 356–359, 383–384

## Q

Quadrigeminal cistern, anatomy of, in third ventricular surgery, 531

Quinagolide, for hyperprolactinemia, 81–82

## R

Rabies-G pseudotyped lentivirus, for gene transfer, for pain management, 425

#### Radiation therapy

for choroid plexus carcinoma, 627–628

for ependymoma, 576

for intraventricular metastasis, 600–602

for meningioma, 563

for neurocytoma, 487–491, 493–501

for pituitary tumors, **147–166**

conformal techniques for, 151–153

conventional techniques for, 149–151

corticotroph adenoma, 142

efficacy of, 147–149

external beam, 147–153, 161–162

in long-term management, **167–171**

in persistent endocrine activity, 140–144

nonfunctioning, 170

planning for, 149

prolactinoma, 143

somatotroph adenoma, 140–141, 168

stereotactic. *See* Stereotactic radiosurgery.

thyrotroph adenoma, 144

toxicity of, 148, 161–163

for subependymoma, 583–584

#### Radiosurgery

for intraventricular meningioma, 563

gamma knife

for neurocytoma, 498, 501

for pituitary tumors, 156–161

for somatotroph adenoma, 83

linear accelerator-based

for neurocytoma, 501

for pituitary tumors, 155–156

proton beam, for pituitary tumors, 154–155

stereotactic. *See* Stereotactic radiosurgery.

Raspberry, William, on psychiatric neurosurgery regulations, 314

Rathke's cleft cyst, imaging of, 63

Rathke's pouch, in pituitary embryogenesis, 11–12

Regulation, of neuropsychiatric surgery research, 312–315

Renal cell carcinoma, intraventricular metastasis from, 595–598

Respiratory depression, in intrathecal pain management, 358

Respiratory disorders, in acromegaly, 44

Retroviruses, for gene transfer, for pain management, 425

Richardson, Alan, limbic leukotomy procedure of, 193

Rosettes, in ependymoma, 473, 573

Rous sarcoma virus, for gene transfer, for pain management, 422

Ryan, J. Kenneth, on psychiatric neurosurgery, 313

## S

Sacral pain, spinal cord stimulation for, 378

Saline solution, for antidiuretic hormone inappropriate secretion, 128–129

Salt wasting, cerebral, after pituitary surgery, 128

Sandostatin  
for somatotroph adenoma, 83, 140  
for thyrotroph adenoma, 144

Sarcoidosis, of pituitary, 71

Schizophrenia  
lobotomy for, 308  
transcranial magnetic stimulation for, 293

Schwannoma, parasellar, imaging of, 70

Scintigraphy, in somatotroph adenoma, 45

Secondary gain, in pain  
chronic, 349  
evaluation of, before management, 415

Seizures. *See also* Epilepsy.  
in lateral ventricle tumor surgery, 523  
in precentral stimulation, 438, 441  
induction of, in transcranial magnetic stimulation, 294–295

Selective serotonin reuptake inhibitors, for obsessive-compulsive disorder, 200

Sellar tumors, anatomic considerations in, 15–16, 57

Sensitization  
central, 450–452  
peripheral, 449–450

Sensory disorders  
in lateral ventricle tumors, 510  
in third ventricular tumor surgery, 542

Septum pellucidum  
anatomy of, 511  
variants of, 608–609

Seroma, in intrathecal medication delivery, 358

Shock therapies, for psychiatric disorders, 184

Single-photon emission computed tomography  
in depression, in vagus nerve stimulation, 279  
in neurocytoma, 484  
in obsessive-compulsive disorder, **237–250**  
diagnostic, 238, 241–242  
postoperative, 238–241, 245–249

Skin disorders, in acromegaly, 44

Skull base, anterior, exposure of, in pituitary surgery, 100–101

Smoking, pain management and, 343

Social Security programs, for chronic pain, 349–350

Somatosensory cortex, in nociception, 448

Somatosensory evoked potentials, in precentral stimulation, 439

Somatostatin, intrathecal delivery of, 361

Somatostatin analogues  
for somatotroph adenoma, 83, 140  
for thyrotroph adenoma, 84, 144

Somatotroph(s), 25

Somatotroph adenoma  
acromegaly in, 43–45  
after pituitary surgery, 134, 139–141  
long-term management of, 168–169  
medical treatment of, 82–83  
persistent, 139–141  
densely granulated, 26–27  
diagnosis of, 45  
long-term management of, 168–169  
medical treatment of, 140, 168  
mixed cell, 27–29  
outcome of, 168–169  
pathology of, 26–29  
persistent, 139–141  
radiotherapy for, 140–141  
sparsely granulated, 27

- Somatotroph (*continued*)  
 surgical treatment of  
 persistent, 139–140  
 postoperative endocrine management in,  
 131, 134
- Somatotroph-lactotroph adenoma, 27
- SPECT. *See* Single-photon emission computed tomography.
- Speech disorders, in lateral ventricle tumor surgery, 523–524
- Spinal cord  
 compression of, in intrathecal medication delivery, 358  
 dorsal horn of, reorganization of, in sensitization, 451  
 dorsal root ganglia of, in nociception, 445–446  
 laminar organization of, nociception and, 446–447
- Spinal cord stimulation, **365–380**  
 advantages of, 366  
 applications of, 366–367, 377–378  
 complications of, 374–377  
 equipment for, 371–372  
   in neuropathic pain, 378  
   in peripheral nerve stimulation, 377–378  
 failure of, 377, 410  
 history of, 331–332, 365  
 lead implants in, 372–374  
 outcomes of, 367, 369–370, 409–412  
 patient selection for, 367–370  
 psychologic variables in, 409–412  
 screening trial in, 371  
 technique for, 370–375  
 terminology of, 366
- Spinal nucleus, in nociception, 447
- Spindle cells, in subependymal giant cell astrocytoma, 475–476, 584
- Spinothalamic tract  
 interruption of, for pain, 328  
 lateral, in nociception, 446–447
- Stereotactic biopsy, in third ventricular tumors, 528
- Stereotactic radiosurgery  
 for intraventricular metastasis, 601–602  
 for neurocytoma, 498–501  
 for pituitary tumors, 153–161  
   gamma knife, 83, 156–161  
   historical view of, 6, 8  
   linear accelerator-based, 155–156  
   nonfunctioning, 170  
   prolactinoma, 90–91  
   proton beam, 154–155  
   somatotroph adenoma, 141  
   toxicity of, 162–163
- Stereotactic surgery  
 cingulotomy. *See* Cingulotomy.  
 for pain, 328, 438–439  
 history of, 190–193
- Stereotactic systems, in lateral ventricle tumors, 514
- Stimulation, electrical. *See* Electrical stimulation.
- Stroke, after pituitary radiotherapy, 162–163
- Subcaudate tractotomy, for psychiatric disorders, 193  
 depression, 204–205, 207, 218  
 obsessive-compulsive disorder, 204–205, 207, 218, 231–232  
 versus cingulotomy, 231–232
- Subcutaneous implantation, for peripheral nerve stimulation, 403–406
- Subdural hematoma, in third ventricular tumor surgery, 542
- Subependymal giant cell astrocytoma, 470–471, 475–476, 584–585
- Subependymal glomerate astrocytoma, 581–582
- Subependymoma, intraventricular, 578–584  
 asymptomatic, 579  
 clinical presentation of, 579  
 differential diagnosis of, 475  
 epidemiology of, 474, 578–579  
 genetic features of, 475  
 pathology of, 474–475, 579–582  
 prognosis for, 583–584  
 radiography in, 579  
 treatment of, 583–584  
 versus ependymoma, 472
- Subfrontal approach, anterior, to pituitary tumors, 104
- Sublabial transsphenoidal approach, to pituitary tumors, 2–4, 7, 94–99
- Subnucleus caudalis, in nociception, 447
- Suboccipital approach, midline, to intraventricular meningioma, 566, 568
- Substance abuse  
 evaluation of, before pain management, 415  
 treatment of, before pain management, 348
- Substance P, in nociception, 446, 452, 454

Substantia gelatinosa, in nociception, 446

Superior parietal occipital approach, to intraventricular meningioma, 565

Superoxide dismutase gene transfer, for pain management, 430

Supraorbital approach, to parasellar and suprasellar lesions, 119–121

Supraorbital pain, peripheral nerve stimulation for, 405

Suprasellar approach, to third ventricular tumors, 532–538

Suprasellar tumors. *See* Parasellar and suprasellar lesions.

Sympathetic nervous system, peripheral sensitization in, 450

Synaptophysin  
in choroid plexus tumors, 470  
in neurocytoma, 485

Syndrome of inappropriate antidiuretic hormone secretion, after pituitary surgery, 126–129

## T

Talairach capsulotomy procedure, 191

Tegmentum, anatomy of, in endoscopic surgery, 549

Tela choroidea, anatomy of, in third ventricular surgery, 531

Temporal gyrus, middle, approach to, to intraventricular meningioma, 564–565

Temporal horn, anatomy of, 512

Temporal transcortical (middle temporal gyrus) approach, to lateral ventricle tumors, 518–519

Tetracycline, for gene transfer, for pain management, 422

Thalamocortical dysrhythmia, **251–265**  
pathophysiology of, 251, 259, 262  
surgery for, 252–263  
magnetoencephalography with, 253–256, 260  
patient selection for, 252  
results of, 255, 259–263  
strategy for, 252–253, 259

Thalamostriate vein, anatomy of, 512–513

Thalamotomy  
central lateral, for thalamocortical dysrhythmia, 252–263

magnetoencephalography with, 253–256, 260

patient selection for, 252

results of, 255, 259–263

strategy for, 252–253, 259

dorsomedial, for psychiatric disorders, 191

## Thalamus

anatomy of, 511, 529

connections to

in depression, 216–219

in obsessive-compulsive disorder, 214, 218–219

electrical stimulation of. *See* Deep brain stimulation.

nuclei of, in nociception, 447–448

ventrobasal, electrical stimulation of, 332–333

Thermal injury, central sensitization in, 450–451

Thermocapsulotomy, for psychiatric disorders, 204–208

Thiazide diuretics, for diabetes insipidus, 132

## Third ventricular tumors, **527–545**

endoscopic resection of, 551–552, 554–555

hydrocephalus in, treatment of, 528

pathology of, 527

radiography in, 528

surgical approaches to

aims of, 527–528

anatomic considerations in, 528–531

complications of, 542

infratentorial supracerebellar, 532–538

interhemispheric transcallosal, 532, 534, 538–539

intraoperative considerations in, 541

occipital transtentorial, 532, 539–541

positioning for, 533–534

postoperative care in, 542

selection of, 531–532

Thirst, in diabetes insipidus, after pituitary surgery, 125

Thyroid stimulating hormone, 19, 25

pituitary tumors secreting. *See* Thyrotroph adenoma.

preoperative management of, in pituitary tumors, 94

Thyrotroph(s), 25

Thyrotroph adenoma

diagnosis of, 49–50

differential diagnosis of, 49–50

hyperthyroidism in, 48–50

medical treatment of, 84, 143–144

- Thyrotroph (*continued*)  
 pathology of, 32–33  
 radiotherapy for, 144  
 surgical treatment of  
   persistent, 143  
   postoperative endocrine management in, 131–132, 134  
   preoperative management in, 94
- Tics, transcranial magnetic stimulation for, 293
- Tourette syndrome  
 neuroimaging and neurocircuitry in, 214  
 transcranial magnetic stimulation for, 293
- Tractotomy, subcaudate, for psychiatric disorders, 193  
 depression, 204–205, 207, 218  
 obsessive-compulsive disorder, 204–205, 207, 218, 231–232  
 versus cingulotomy, 231–232
- Transcallosal approaches  
 to lateral ventricle tumors  
   anterior, 520–521  
   posterior, 521–522  
 to third ventricular tumors, 532, 534, 538–539
- Transcortical approaches, to lateral ventricle tumors, 517–520
- Transcranial approaches  
 to parasellar and suprasellar lesions, **109–122**  
 to pituitary tumors, 4–5, 93–94, 103–104
- Transcranial magnetic stimulation, **283–301**  
 animal models of, 287  
 drug use with, 293  
 electrical requirements of, 285  
 for anxiety disorders, 293–294  
 for depression, 288–293  
   maintenance, 292  
   meta-analysis of, 289–292  
   with intentional seizure generation, 294–295  
 for eloquent cortex localization, 287  
 for epilepsy, 286–287, 293  
 for mania, 292  
 for movement disorders, 293  
 for schizophrenia, 293  
 functional imaging with, 287–288  
 high-frequency, 285–286  
 mechanisms of action of, 284–286  
 paired-pulse, 286–287  
 repetitive, 284  
 research uses of, 286–288  
 safety of, 286  
 versus electroconvulsive therapy, 287–289, 291–292, 294
- Transmaxillary transsphenoidal approach, 102–103
- Transorbital lobotomy, 189
- Transposons, for gene transfer, 421
- Transsphenoidal approach, to pituitary tumors, 93–103  
 anterior skull base exposure in, 100–101  
 cavernous sinus exposure in, 102  
 clivus exposure in, 101–102  
 combined transmaxillary, 102–103  
 Cushing technique for, 2–5, 7  
 Dott technique for, 5–7  
 endonasal, 1–2, 99–100  
 endoscope-assisted, 104–105  
 extended, 100–102  
 Guiot technique for, 6, 8  
 Hardy technique for, 8–10  
 Hirsch technique for, 1–2  
 historical overview of, **1–10**  
 sublabial, 94–99
- Transtentorial approach, to third ventricular tumors, 532, 539–541
- Transzygomatic approach, to parasellar and suprasellar lesions, 109–111
- Trichotillomania, neuroimaging and neurocircuitry in, 214
- Trigeminal mesencephalic nucleus, in nociception, 447
- Trigeminal nerve, in nociception, 446–447
- Trigeminothalamic tract, in nociception, 447
- Tuber cinereum, anatomy of, in endoscopic surgery, 549
- Tuberculosis, of pituitary, 71
- Tuberin, in subependymal giant cell astrocytoma, 476
- Tuberous sclerosis complex, 615–617  
 subependymal giant cell astrocytoma in, 475–476, 584–585
- Tumor(s)  
 intraventricular. *See* Intraventricular tumors.  
 pituitary. *See* Pituitary tumors.
- 
- U**
- Ultrasonography, in lateral ventricle tumors, 514
- Urinary free cortisol test, in corticotroph adenoma, 46

**V**

---

- Vagus nerve, electrical stimulation of  
clinical applications of, 280  
for depression, **275–282**  
anatomic considerations in, 275  
clinical trials of, 276  
long-term results of, 278–279  
mechanism of action of, 277, 279–280  
open-label study of, 277–278  
placebo-controlled study of, 278–279  
practical considerations in, 280–281  
preclinical investigations of, 275–276
- Valentine, Elliot S., on psychiatric neurosurgery, 312
- Vascular proliferation, in central neurocytoma, 487
- Vasopressin. *See* Antidiuretic hormone.
- Vein of Galen, anatomy of, in third ventricular surgery, 531
- Velum interpositum, anatomy of, in third ventricular surgery, 531
- Ventricles, tumors in. *See* Intraventricular tumors.
- Ventriculotomy. *See* Endoscopy, in intraventricular surgery.
- Ventriculostomy, third, endoscopic, 551–552
- Ventroposterior nucleus, in nociception, 447

- Vesiculostomatitis virus, for gene transfer, for pain management, 425

**Vimentin**

- in choroid plexus tumors, 470  
in ependymoma, 473

- Viral vectors, for gene transfer, for pain management, 421–425

**Visual disorders**

- after pituitary radiotherapy, 162–163  
in lateral ventricle tumor surgery, 52  
in neurocytoma, 483  
in prolactinoma, 29  
in third ventricular tumor surgery, 542

**W**

---

- Watts, James, psychiatric neurosurgical procedures of, 185–187, 189
- Weinberger, Lawrence M., on ethics of neuropsychiatric surgery, 306
- Wide dynamic range cells, in nociception, 446–447
- Withdrawal reactions, in intrathecal pain management, 359
- Work, return to, after pain management, psychosocial issues in, 347–348
- Workers' compensation systems, pain management and, 341, 349–350